NIH-supported Clinical Trial Tests Experimental Dengue Treatment

A New Frontier in Dengue ⁣Treatment: A Monoclonal ⁣Antibody⁤ Trial⁢ Shows Promise

Dengue fever, a mosquito-borne illness affecting hundreds of ⁤millions worldwide, poses a meaningful public health threat. ⁤ The disease, characterized by ⁢severe⁣ headaches, body aches, nausea, ⁢fever, and a ​distinctive rash, can progress to life-threatening complications in one in twenty cases. ⁤Currently, there is no FDA-approved treatment for dengue, leaving healthcare ‍providers‌ with limited options for critically ill patients.

“When‌ caring for a patient who is critically ill with⁢ dengue, healthcare ⁤providers⁣ have few⁢ options ‌other than providing supportive ‍care. We‌ must find safe and⁢ effective therapeutics to‍ provide much-needed⁢ relief to people suffering⁣ from dengue,”⁢ explains Dr. Jeanne ‍Marrazzo, Director of the National Institute of⁣ Allergy and Infectious Diseases (NIAID).

Hope ⁢is on the horizon⁤ with a new phase 2‌ clinical trial, supported by the National‌ Institutes of Health (NIH), that is investigating the potential of AV-1, an experimental ‌human monoclonal ⁤antibody developed by AbViro. This investigational therapeutic is designed to mitigate the symptoms of dengue virus infection⁤ when ‍administered​ both before and⁤ after exposure.

The Phase​ 2 trial will ‍enroll 84 healthy adult volunteers across two⁤ sites: the Johns Hopkins Bloomberg School of Public Health Center for ​Immunization Research⁣ in Baltimore and the‌ University of Vermont vaccine Testing Center in Burlington.⁢ ⁤ Participants will be randomly assigned​ to ‌receive‌ either AV-1 one day before or four days after being challenged with a‌ weakened strain of the dengue virus. The study will assess⁢ the safety and efficacy of three different dosage ⁣levels of AV-1 (100 mg,⁣ 300 mg,‌ and 900 ⁤mg) administered intravenously.Prior research,⁤ including a Phase 1 trial also supported by ⁢the ⁤NIAID, has already demonstrated‌ the safety of AV-1 in humans, paving the way for this larger trial. Previous studies using the attenuated dengue virus challenge⁣ have shown ‍that most volunteers develop a rash and some experiance mild symptoms, such as joint and muscle pain or headache. However, no ‍volunteers​ have developed dengue fever ⁢or severe dengue.

This new trial holds significant promise for finding a much-needed treatment ⁢for dengue.If‍ accomplished, further⁢ clinical‌ evaluations‌ will be pursued to determine​ the full potential of AV-1 in combating this serious‌ global health concern. For more detailed details about the ​study,you can visit ClinicalTrials.gov and ​search for the identifier‌ NCT06799741.

What are the potential key⁣ outcomes of the Phase 2 clinical trial?

A New Frontier in Dengue Treatment: An Interview with Dr.⁢ Sarah ⁣Chen

Dengue fever, a mosquito-borne illness affecting hundreds of millions worldwide, poses⁢ a important public ⁣health threat. Currently, there is no FDA-approved⁣ treatment for dengue, leaving healthcare providers with limited ⁤options ‍for critically ill patients. Though, a new phase ​2‌ clinical trial is investigating⁣ the ⁢potential of AV-1, an experimental monoclonal antibody, too offer much-needed ‌relief.

Interview with Dr. sarah Chen, Lead Investigator, AV-1 Dengue Trial

Dr. Sarah Chen is the lead investigator for⁤ the Phase 2 clinical trial evaluating the safety and‍ efficacy of AV-1, a⁣ novel monoclonal antibody, in the treatment​ of dengue fever. We spoke with dr. Chen ⁣to learn more about this promising new therapy.

Archyde News: Dr. Chen,⁤ thank you for speaking‍ with us.Can you tell us about the significance‌ of ⁤this trial for patients suffering from ⁤dengue fever?

Dr. Chen: Your welcome. Dengue fever is a serious⁣ disease‌ that can cause debilitating ‌symptoms ⁢and, in severe cases, ‌even death. ⁣Currently, there ‍are no FDA-approved antiviral treatments for dengue. This⁤ trial represents a ‌crucial step forward in our ‍quest to⁣ develop a⁣ safe and effective therapeutic option⁤ for patients.

Archyde⁣ News: What⁤ makes AV-1 ⁤a unique and promising​ candidate ‍for⁤ dengue treatment?

dr. Chen: AV-1 is a ‌human monoclonal antibody specifically designed to target‌ the​ dengue virus.Unlike existing ‍treatment options,which primarily focus on symptom management,AV-1‌ aims to⁣ directly neutralize the virus,possibly preventing or lessening the severity of the disease.

Archyde News: ‌ How does this trial work, and what are the key objectives?

dr. Chen: The Phase 2 trial is a randomized, placebo-controlled study. We ​will be enlisting ⁣healthy ‍adult ⁣volunteers who ​will be challenged with a weakened strain of the‍ dengue virus. Participants will receive different dosages​ of AV-1 either one ​day⁤ before or four days after exposure to the virus. We will ⁢be carefully monitoring for ​safety and efficacy,assessing the impact of AV-1​ on ‌both the viral load and the⁢ development of⁢ associated symptoms.

Archyde News: What are your hopes for the ​future of AV-1 if this trial is⁣ successful?

Dr. Chen: ⁢ Our hope⁣ is that AV-1 will become a valuable tool in the fight against dengue. If the trial demonstrates promising results, we will move forward with larger-scale​ trials⁤ to further evaluate its safety and effectiveness. Ultimately, we aim to make AV-1 available to patients worldwide, contributing to a significant reduction ‍in the ⁢burden ‌of this debilitating ⁢disease.

Archyde News: What ‌implications could this breakthrough ​have for global health?

Dr. Chen: ‌The potential impact ‍is ⁤enormous. Dengue​ fever affects millions of people⁢ each year, primarily in tropical and subtropical regions.Having an ⁤effective treatment would be ⁣a major public‌ health victory, saving lives and improving the well-being of countless individuals.

Archyde‌ News:⁢ This is truly exciting​ news. Dr. Chen, thank you for your⁤ time ⁤and for your⁣ dedication to this vital research.

Dr. chen: You’re very welcome.